Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2015 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SCPHARMACEUTICALS INC | 19 | Q2 2024 | 7.5% |
CIDARA THERAPEUTICS INC | 18 | Q1 2024 | 1.7% |
HOMOLOGY MEDICINES INC | 17 | Q4 2023 | 26.6% |
ARVINAS INC | 16 | Q3 2023 | 14.3% |
Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
VOR BIOPHARMA INC | 14 | Q2 2024 | 51.9% |
IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
RALLYBIO CORP | 12 | Q2 2024 | 15.0% |
ENTRADA THERAPEUTICS INC | 11 | Q2 2024 | 20.0% |
CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.